KIMBERLY MARTIN: Open Payments
NPI 1063946358 · SALEM, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,534 in 139 payments from 20 companies in 2025. Trend: 2023 $3,717 · 2024 $2,392 · 2025 $3,534
Food & beverage: $3,534
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $672 |
| Janssen Biotech, Inc. | 13 | $501 |
| Madrigal Pharmaceuticals | 9 | $368 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $287 |
| Ipsen Biopharmaceuticals, Inc | 5 | $252 |
| PFIZER INC. | 10 | $227 |
| GENZYME CORPORATION | 4 | $184 |
| Regeneron Healthcare Solutions, Inc. | 6 | $171 |
| Ardelyx, Inc. | 12 | $158 |
| Boston Scientific Corporation | 1 | $123 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, RINVOQ, XIFAXAN, IQIRVO, IBSRELA, SKYRIZI.
Industry payments across VA — which companies pay providers there.
